Samsung Bioepis Co.
Samsung Bioepis Co., Ltd.
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, Republic of Korea
Phone: +82-32-728-0114Website: https://www.samsungbioepis.com/en/index.doCareers: www.samsungbioepis.com/en/careers...
Latest news
- FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva
16 February 2025 - FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia
16 February 2025 - FDA Approves Epysqli (eculizumab-aagh), a Biosimilar to Soliris
22 July 2024 - FDA Approves Pyzchiva (ustekinumab-ttwe), a Biosimilar to Stelara
1 July 2024 - FDA Approves Opuviz (aflibercept-yszy), an Interchangeable Biosimilar to Eylea
20 May 2024 - FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis
20 September 2021 - Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
18 November 2020 - Samsung Bioepis Announces One-Year Results from Phase 3 Study of SB11, a Proposed Biosimilar to Lucentis® (ranibizumab)
11 November 2020 - Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
18 May 2020 - FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel
27 April 2019
Drugs Associated with Samsung Bioepis Co., Ltd.
Samsung Bioepis Co., Ltd. manufactures, markets and/or distributes more than 10 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Byooviz
Generic name: ranibizumab Drug class: anti-angiogenic ophthalmic agents |
||
|
Epysqli
Generic name: eculizumab Drug class: selective immunosuppressants |
||
|
Eticovo
Generic name: etanercept Drug class: antirheumatics, TNF alfa inhibitors |
||
|
Hadlima
Generic name: adalimumab Drug class: TNF alfa inhibitors |
4 reviews | 6.8 / 10 |
|
Ontruzant
Generic name: trastuzumab Drug class: HER2 inhibitors |
||
|
Opuviz
Generic name: aflibercept Drug class: anti-angiogenic ophthalmic agents |
||
|
Ospomyv
Generic name: denosumab Drug class: miscellaneous bone resorption inhibitors |
||
|
Pyzchiva
Generic name: ustekinumab Drug class: interleukin inhibitors |
||
|
Renflexis
Generic name: infliximab Drug class: TNF alfa inhibitors |
8 reviews | 7.1 / 10 |
|
Xbryk
Generic name: denosumab Drug class: miscellaneous bone resorption inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||